Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-05-31
2005-05-31
Woitach, Joseph (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C435S069100, C435S325000, C424S093100, C424S191100, C536S063000
Reexamination Certificate
active
06900049
ABSTRACT:
The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.
REFERENCES:
patent: 5648478 (1997-07-01), Henderson
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5834306 (1998-11-01), Webster et al.
patent: 5871726 (1999-02-01), Henderson et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 2003/0095989 (2003-05-01), Irving et al.
patent: 0845537 (1998-06-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 95/11984 (1995-05-01), None
patent: WO 95/14100 (1995-05-01), None
patent: WO 95/14100 (1995-05-01), None
patent: WO 96/17053 (1996-06-01), None
patent: WO 96/34969 (1996-11-01), None
patent: WO 96/34969 (1996-11-01), None
patent: WO-97/01358 (1997-01-01), None
patent: WO 98/06864 (1998-02-01), None
patent: WO 98/06864 (1998-02-01), None
patent: WO 98/13508 (1998-04-01), None
patent: WO 98/35028 (1998-08-01), None
patent: WO 98/35028 (1998-08-01), None
Cuevas et al. Cancer Res 63:6877-6884, October 15, 2003.*
Hernandez-Alcoceba et al. Human Gene Therapy 13:1737-1750, Sep. 20, 2002.*
Li et aI abstract 445 from ASGT 71h Annual Meeting, Jun. 2004.*
Babiss et. al.; Cellular Promoters Incorporated into the Adenovirus Genome; 1987, J. Mol. Biol. 193: 643-650.*
Shi et. al.; Modulation of the Specificity and Activity of a Cellular Promoter in an Adenoviral Vector; 1997, Human Gene Therapy 8: 403-410.*
Bett et. al., packaging Capacity and Stability of Human adenovirus Type 5 Vectors, 1993, Journal of Virology, Vol. 67, No. 10: 5911-5921.*
Anderson; Human gene therapy, 1998, Nature Vol. 392: 25-30.*
Verma et. al.; Gene therapy-promises, problems and prospects, 1997, Nature, Vol. 389:239-242.*
Curiel; Strategies to Adapt Adenoviral Vectors forTargeted Delivery, 1999, Gene Therapy Strategies:158-171.*
Jam; Delivery of moleculat and cellular medicine to solid tumors, 1997, Journal of Controlled Release 53: 49-87.*
Hobbs; Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment, 1998, Proc. Natl. Acad. Sci. Vol. 95: 4607-4612.*
Walther; Targeted Vectors for Gene therapy of Cancer and Retrpvoral Infections, 1996, Molecular Biotechnology Vol. 6: 2670286.*
Dachs; Targeted Gene Therapy to Cancer: A Review. 1997, Oncolog Research Vol. 9: 313-325.*
Advani et. al.; Radiogenetic Therapy: On the Interaction of Viral therapy and Ionizing Radiation for improving Local Control of Tumors, 1997, Seminars in Oncology Vol. 24. No. 6: 633-638.*
Parr et. al..; Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector, 1997, Nature medicine Vol. 3, No. 3: 1145-1949.*
Orkin et al., “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.” pp. 1-20, Dec. 1995.*
Miller et al., “Targeted Vector for Gene Therapy.” FASEB, Vol. 9: 190-199, Feb. 1995.*
Ledley, F 0.,“Pharmaceutical Approach to Somatic Gene Therapy.” Pharmaceutical Research vol. 13: 1595-1613, Nov. 1996.*
Eck et al “Gene-Based Therapy-Chapter 5.”, Goodman & Gilman's The Pharmacological Basis of Therapeutics-Ninth Edition, McGraw-Hill: 77-101, 1996.*
Abe et al. (1993). “Characterization of Cis-Acting Elements Regulating Transcription of the Human DF3 Breast Carcinoma-Associated Antigen (N4UCI) Gene,”Proc. Natl. Sci. USA90: 282-286.
Arnberg et al. (1997). “Fiber Genes of Adenoviruses with Tropism for the Eye and the Genital Tract,”Virol.227: 239-244.
Ausubel et al. eds. (1987). Current Protocols in Molecular Bioloev Suppl. 30 Sec. 7.7.18, Table 7.7.1.
Bailey et al. (1993). “Enteric Adenovirus Type 40: Expression of EIB Proteins in Vitro and in Vivo,”Virol.193: 631-641.
Bailey et al. (1994). “Cell Type Specific Regulation of Expression from the Ad40 E1 B Promoter in Recombinant Ad5/Ad40 Viruses,”Virol.202: 695-706.
Behringeret al. (1988). “Dwarf Mice Produced by Genetic Ablation of Growth Hormone-Expressing Cells,”Genes Dev.2: 453-461.
Berkner et al. (1983). “Generation of Adenovirus by Transfection of Plasmids,”Nuc. Acid Res.11(17): 6003-6020.
Bett et al. (1993). “Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors,”J. Virol.67(10): 5911-5921.
Bett et al. (1994) “An efficient and Flexible System for Construction of Adenovirus Vectors with insertions or Deletions in Early Regions 1 and 3,”Proc. Nail. A cad. Sci. USA91: 8802-8806.
Bridge et al. (1989). “Redundant Control of Adenovirus Late Gene Expression by Early Region 4,”J. Virol.63(2): 631-638.
Bunn et al. (1996). “Oxygen Sensing and Molecular Adaptation to Hypoxia,”Physiol. Rev.76(3): 839-885.
Cannio et al. (1991). “A Cell-Type Specific and Enhancer-Dependent Silencer in the Regulation of the Expression of the Human Urokinase Plasminogen Activator Gene,”Nuc. Acids Res.19(9): 2303-2308.
Coiditz. (1993). “Epidemiology of Breast Cancer,”Cancer Suppl.71(4): 1480-1489.
Dachs et al. (1996). “The Molecular Response of Mammalian Cells to Hypoxia and the Potential for Exploitation in Cancer Therapy,”Br. J. Cancer74: 5 126-5132.
Dachs et al. (1997). “Targeting Gene Expression to Hypoxic Tumor Cells,”Nat. Med.3(5): 515-520.
Feigner et al. (1989). “Cationic Liposome-Mediated Transfection,”Nature337: 387-388.
Firth et al. (1994). “Oxygen-Related Control Elements in the Phosphoglycerate Kinase 1 and Lactate Dehydrogenase A Genes: Similarities with the Erythropoietin 3′ Enhancer,”Proc. Nati. Acad. Sci. USA91: 6496-6500.
Flint. (1982). “Expression of Adenoviral Genetic Information in Productively infected Cells,”Biochem. Biophys. Acta651: 175-208.
Flint. (1986). “Regulation of Adenovirus mRNA Formation,”Adv. Vir. Res.31: 169-228.
Folkman. (1989). “What is the Evidence that Tumors are Angiogenesis Dependent?”Natl. Cancer Inst.82(1): 4-6.
Frankel et al. (1989). “Selection and Characterization of Ricin Toxin A-Chain Mutations inSaccharomyces cerevisiae,” Mol. Cell. Biol.9(2): 4 15-420.
Graham. (1984). “Covalently Closed Circles of Human Adenovirus DNA are Infectious,”EMBO J.3(12): 2917-2922.
Grand. (1987). “The Structure and Functions of the Adenovirus Early Region 1 Proteins,”Biochern. J.241: 25-38.
Grooteclaes et al. (1984). “The 6-Kilobase c-erbB2 Promoter Contains Positive and Negative Regulatory Elements Functional in Human Mammary Cell Lines,”Cancer Res.54: 4193-4199.
Guillemin et al. (1997). “The Hypoxie Response: Huffing and HIFing,”Cell89: 9-12.
Hallahan et al. (1995). “Spatial and Temporal Control of Gene Therapy Using Ionizing Radiation,”Nat. Med1(8): 786-791.
Höckel et al. (1996). “Hypoxia and Radiation Response in Human Tumors,”Semin. Rad. Oncol.˜6(1): 3-9.
Hudson Ct al. (1990). “Structure and Inducible Regulation of the Human c-crb B2Ineu Promoter,”J. Biol. Chem.265: 4389-4393.
Ido et al. (1995). “Gene Therapy for 1-lepatoma Cells Using a Retrovirus Vector Carrying Herpes Simplex Virus Thymidine Kinase Gene Under the Control of Human ci-Fetoprotein Gene Promoter,”Cancer Res.55: 3105-3109.
Ishii et al. (1987) “Characterization of the Promoter Region of the Human C-erb B-2 Protooncogene,”Proc. Nati. Acad. Sci. USA84: 4374-4378.
Jiang et al. (1997). “V-SRC Induces Expression of Hypoxia-inducible Factor 1(HIF-1) and Transcription of Genes Encoding Vascular Endothelial Growth Factor and Enolase 1: Involvement of HIF-1 in Tumor Progression,”Can. Res.57: 5328-5335.
Johnson et al
Henderson Daniel R.
Yu De Chao
Boziecevic, Field & Francis LLP
Cell Genesys Inc.
Judge Linda R.
Sherwood Pamela J.
Woitach Joseph
LandOfFree
Adenovirus vectors containing cell status-specific response... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenovirus vectors containing cell status-specific response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenovirus vectors containing cell status-specific response... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3436077